A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions
| Status: | Recruiting | 
|---|---|
| Healthy: | No | 
| Age Range: | 21 - Any | 
| Updated: | 11/3/2018 | 
| Start Date: | June 29, 2017 | 
| End Date: | August 2020 | 
A Prospective, Randomized, Multi-Center, Open-Label Pilot Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions
The purpose of this study is to obtain safety and effectiveness data on the investigational
device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use
in this indication. The study information may be used for a potential pivotal study design.
			device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use
in this indication. The study information may be used for a potential pivotal study design.
Inclusion Criteria:
1. Degenerative lumbar spine condition:
1. Requiring a PLF procedure using a bilateral metallic screw and rod system in 2-4
consecutive levels from L2-S1; and
2. Diagnosed with: instability (up to and including Grade 2 spondylolisthesis,
retrolisthesis, or lateral listhesis), stenosis with documented pre-operative
instability, and/or recurrent disc herniation, any of which may have possible
concomitant lumbar degenerative deformity (Cobb angle ≤ 30 degrees).
2. Preoperative ODI score ≥40.
3. Preoperative pain score of ≥8 (out of 20) on the Preoperative Leg Pain Questionnaire.
4. Most inferior treated spinal level is able to accommodate an interbody fusion device.
5. ≥21 years of age at the time of signing the informed consent.
6. Failed ≥6 months non-operative treatment (e.g., bed rest, physical therapy,
medications, spinal injections, manipulation, and/or TENS).
7. Is willing and able to comply with the study plan and able to understand and sign the
Subject Informed Consent Form.
Exclusion Criteria:
1. Prior spinal fusion surgical procedure at the involved or adjacent spinal levels.
(Prior non-fusion surgery at the target levels, including discectomy and/or
single-level foraminotomy or laminectomy, is allowed.)
2. Prior lumbar disc arthroplasty.
3. Significant lumbar instability, defined as sagittal listhesis >Grade 2 at any involved
level using Meyerding's Classification or lateral listhesis >25% lateral translation
at any involved level.
4. Planned use of an internal or external bone growth stimulator.
5. Lumbar scoliosis >30 degrees.
6. Osteoporosis to a degree that spinal instrumentation is contraindicated or a history
of atraumatic vertebral fracture.
7. Morbidly obese, as defined by a Body Mass Index (BMI) >40.
8. Presence of active malignancy or prior history of malignancy.
9. Overt or active bacterial infection, either local or systemic.
10. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic,
immunostimulating, or immunosuppressive agents within 30 days prior to implantation of
the assigned treatment.
11. Comorbidities precluding subject from being a surgical candidate.
12. History of autoimmune disease known to affect bone metabolism or the spine (e.g.,
spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease,
Hashimoto's thyroiditis).
13. History of any endocrine or metabolic disorder known to affect osteogenesis (e.g.,
Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis
imperfecta).
14. History of exposure to any recombinant proteins used for bone formation (i.e., Infuse
Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide
Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft).
15. Hypersensitivity or allergy to any components of the study treatments including, but
not limited to, bone morphogenetic proteins (BMPs); injectable collagen; protein
pharmaceuticals (e.g., monoclonal antibodies or gamma globulins); bovine collagen
products; gentamicin or glycerol (which may be present in trace amounts in the DBM
products); and/or instrumentation materials (titanium, titanium alloy, cobalt chrome,
cobalt chrome alloy, or polyetheretherketone [PEEK]).
16. History of any allergy resulting in anaphylaxis.
17. Is a prisoner.
18. Is mentally incompetent. If questionable, obtain psychiatric consult.
19. Treatment with an investigational therapy (drug, device, and/or biologic) within 30
days prior to implantation surgery, or such treatment is planned during the 24-month
period following implantation of the study treatment.
20. Pregnant or nursing. Females of child-bearing potential must agree not to become
pregnant for one year following surgery.
21. Any condition that would interfere with the subject's ability to comply with study
instructions, might confound the interpretation of the study, or put the subject at
risk.
We found this trial at
    13
    sites
	
									524 South Park Street
Kalamazoo, Michigan 49007
	
			Kalamazoo, Michigan 49007
(269) 341-7654 
							
					Principal Investigator: Gregory Wiggins, MD
			
						
										Phone: 269-720-6759
					
		Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...  
  
  Click here to add this to my saved trials
	
									201 Dowman Dr
Atlanta, Georgia 30303
	
			Atlanta, Georgia 30303
(404) 727-6123
							
					Principal Investigator: Keith Michael, MD
			
						
										Phone: 404-778-6857
					
		Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...  
  
  Click here to add this to my saved trials
	
									711 East Altamonte Drive
Altamonte Springs, Florida 32701
	
			
					Altamonte Springs, Florida 32701
Principal Investigator: Chetan Patel, MD
			
						
										Phone: 407-303-2367
					Click here to add this to my saved trials
	
								Austin, Texas 78731			
	
			
					Principal Investigator: Eeric Truumees, MD
			
						
										Phone: 512-324-3580
					Click here to add this to my saved trials
	
								Carmel, Indiana 46032			
	
			
					Principal Investigator: Joseph Smucker, MD
			
						
										Phone: 317-715-5897
					Click here to add this to my saved trials
	
								Charlottesville, Virginia 22903			
	
			(434) 924-0311 
							
					Principal Investigator: Mark E. Shaffrey, MD
			
						
										Phone: 434-982-1856
					
		University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...  
  
  Click here to add this to my saved trials
	
								Durango, Colorado 81301			
	
			
					Principal Investigator: Douglas Orndorff, MD
			
						
										Phone: 970-375-3696
					Click here to add this to my saved trials
	
								East Syracuse, New York 13057			
	
			
					Principal Investigator: William Lavelle, MD
			
						
										Phone: 315-464-8618
					Click here to add this to my saved trials
	
								Fort Wayne, Indiana 46804			
	
			
					Principal Investigator: Kevin A Rahn, MD
			
						
										Phone: 260-436-8686
					Click here to add this to my saved trials
	
								Kansas City, Kansas 66160			
	
			
					Principal Investigator: Paul Arnold, MD
			
						
										Phone: 913-945-8190
					Click here to add this to my saved trials
	
									1 Shields Ave
Sacramento, California 95616
	
			Sacramento, California 95616
(530) 752-1011
							
					Principal Investigator: Kee Kim, MD
			
						
										Phone: 916-734-1652
					
		University of California-Davis As we begin our second century, UC Davis is poised to become...  
  
  Click here to add this to my saved trials
	
									13020 Telecom Parkway North
Tampa, Florida 33637
	
			
					Tampa, Florida 33637
Principal Investigator: John Small, MD
			
						
										Phone: 813-978-9700
					Click here to add this to my saved trials
	
								Vail, Colorado 81657			
	
			
					Principal Investigator: Donald Corenman, MD
			
						
										Phone: 970-479-1587
					Click here to add this to my saved trials